Clinical trials: HIV Seropositivity, active
ANCA-IgG-positive ANCA Associated Vasculitis
Anti-CD 19 CAR-T Cell Therapy in Patients With ANCA Vasculitis
The goal of this phase I/II clinical trial is to investigate anti-CD 19 chimeric antigen receptor T cell (CAR-T cell) therapy in patients with antineutrophil cytoplasmic antibodies (ANCA) immunoglobulin (IgG) positive ANCA…
- Trial name
- IDEAL (NCT06590545)
- Testing
- KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapy
- Volunteers
- 8 people
- Sponsor
- David Simon
Treponema Pallidum, Treponema Pallidum Infection
This Study Evaluates the ALPCO Syphilis-T and Syphilis-NT CLIA Kits for Detecting Syphilis Antibodies in Serum and Plasma. Samples From At-risk, HIV-positive, Pregnant, and Healthy Individuals Will Assess Assay Performance Versus Established Comparator Tests.
This study will evaluate the clinical performance of two investigational diagnostic kits developed by ALPCO: the Syphilis-T CLIA Kit and the Syphilis-NT CLIA Kit.
- Conditions
- Treponema Pallidum, Treponema Pallidum Infection, Syphilis Infection, Serum
- Trial name
- NCT07089836
- Testing
- ALPCO Syphilis-T, ALPCO Syphilis-NT CLIA Kits
- Where
- 6 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- American Laboratory Products Company
HIV Positive
Thinking and Memory Problems in People With HIV
Background: People with human immunodeficiency virus (HIV) can sometimes develop thinking and memory problems. These problems can vary widely, from few symptoms to severe problems with memory and concentration.
- Trial name
- NCT01875588
- Where
- United States
- Volunteers
- 1,150 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
HIV-1-infection, HIV Seropositivity
Immuno-virological Evaluation of Persons Living With HIV (PLWH)
This is a dual arm (arm 1 and arm 2) multi-centric non-randomized (prospective) study. Two new multicentric cohorts will be set up in 4 Belgian HIV reference centers (UZ Gent, UZ Brussel, University Hospital Liege and St.
- Trial name
- NCT05973825
- Testing
- Leucapheresis
- Where
- Belgium
- Volunteers
- 24 people
- Sponsor
- University Hospital, Ghent
HIV Seropositivity, Tuberculosis
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
A multicenter, randomized, stratified, open-label, phase IV trial among HIV-positive persons (PLHIV) on antiretroviral therapy (ART), or HIV-negative household contacts of patients with rifampicin-sensitive pulmonary tuberculosis…
- Conditions
- HIV Seropositivity, Tuberculosis, Household Contact
- Trial name
- 1 to 3 (NCT05118490)
- Testing
- Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks
- Where
- 4 sites in India, Indonesia and 2 more
- Volunteers
- 1,000 people
- Sponsor
- The Aurum Institute NPC
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hodgkin Lymphoma (Category)
Phase II Trial of BrECADD in HIV-Positive Patients With Advanced-Stage Classical Hodgkin Lymphoma
Participants receive chemotherapy with BrECADD in standard doses and cycle length. After the first two cycles, a restaging is performed by contrast-enhanced computed tomography (ceCT) and PET (PET/CT) in order to guide…
- Trial name
- BASTION (NCT06919679)
- Testing
- BrECADD
- Volunteers
- 35 people
- Sponsor
- University of Cologne
Covid19, Geriatric Medicine
COVID-19 Serology and Immunosenescence
This study aims to determine how long COVID-19 neutralizing antibodies can be detected in an elderly institutionalized population presenting fragility factors.
- Conditions
- Covid19, Geriatric Medicine, Seroconversion, Immunosenescence
- Trial name
- SERO-CoV-OLD (NCT04563650)
- Testing
- blood sample
- Where
- France
- Volunteers
- 98 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
HIV Seropositivity
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
The goal of this phase II, open-label, randomized, controlled clinical trial is to evaluate the impact of Gammora®, a 16-mer HIV integrase-derived peptide associated with a boosted darunavir antiretroviral regimen compared…
- Trial name
- NCT06799650
- Testing
- Gammora®
- Where
- Brazil
- Volunteers
- 40 people
- Sponsor
- Federal University of São Paulo
HIV Seropositivity
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression…
- Trial name
- NCT05723653
- Testing
- Social Network Support Intervention
- Where
- 7 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Idiopathic CD4 T Cell Lymphocytopenia
Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia
Background: Diseases related to human papillomavirus (HPV) include warts, lesions, and cancers. ICL is idiopathic CD4 T cell lymphocytopenia. People with this rare disease get more HPV-related diseases than other people do.
- Trial name
- NCT03519464
- Testing
- Gardasil 9
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Seropositivity
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
What is known: There are 1.2 million people in the US who meet the indications for PrEP; yet, disparities exist in uptake. For example, only 9% of Black and 16% of Latino individuals, compared to 65% of White individuals, have…
- Trial name
- MOST:PrEP (NCT06334341)
- Testing
- Computer-based simulation training for providers, Best Practice Alert, HIV Risk Assessment
- Where
- United States
- Volunteers
- 1,380 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
HIV, Seroconversion, HIV
Accurate Staging of Immuno-virological Dynamics During Acute HIV Infection
In this prospective longitudinal study we aim to assess how immunologic and viral aspects of the human immunodeficiency virus (HIV) viral reservoir, established during early HIV infection and responsible for viral rebound at…
- Trial name
- ACS (NCT03449706)
- Testing
- Early combination anti-retroviral treatment
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
HIV Seropositivity, Pregnancy
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Open-label, two-arm, randomized multicenter study to investigate the safety, tolerability, and pharmacokinetics (PK), and potential interactions between dolutegravir (DTG) and rifapentine (RPT) during pregnancy in people with HIV…
- Conditions
- HIV Seropositivity, Pregnancy, Tuberculosis Infection
- Trial name
- DOLPHIN Moms (NCT05122026)
- Testing
- Rifapentine, Isoniazid
- Where
- 3 sites in South Africa
- Volunteers
- 252 people
- Sponsor
- The Aurum Institute NPC